Table 3.
Prevalence of Pfmdr1 polymorphisms in pre-treatment and post-treatment samples stratified by treatment arms, therapeutic efficacy monitoring, Mali, 2015–2016
| AL arm | ASAQ arm | |||||
|---|---|---|---|---|---|---|
| Pre-treatment n, (%) | Post-treatment n, (%) | p-value* | Pre-treatment n, (%) | Post-treatment n, (%) | p-value* | |
| Pfmdr1 point mutations | ||||||
| Pfmdr1 codon 86 | n = 126 | n = 36 | n = 120 | n = 27 | ||
| N86 | 103 (81.7) | 35 (97.2) | 0.1954 | 97 (80.8) | 22 (81.5) | 0.767 |
| 86N/Y | 9 (7.1) | 0 (0.0) | 5 (4.2) | 2 (7.4) | ||
| 86Y | 14 (11.1) | 1 (2.8) | 18 (15.0) | 3 (11.1) | ||
| Pfmdr1 codon 184 | n = 144 | n = 36 | n = 140 | n = 26 | ||
| Y184 | 44 (30.6) | 7 (19.4) | 0.1029 | 38 (27.1) | 5 (19.2) | 0.464 |
| 184Y/F | 19 (13.2) | 0 (0.0) | 15 (10.7) | 3 (11.5) | ||
| 184F | 81 (56.3) | 29 (80.6) | 87 (62.1) | 18 (69.2) | ||
| Pfmdr1 codon 1246 | n = 152 | n = 39 | n = 146 | n = 25 | ||
| D1246 | 149 (98.0) | 39 (100.0) | 1 | 144 (98.6) | 24 (96.0) | 1 |
| 1246D/Y | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.0) | ||
| 1246Y | 3 (2.0) | 0 (0.0) | 2 (1.4) | 0 (0.0) | ||
| Pfmdr1 haplotypes† | n = 124 | n = 35 | n = 115 | n = 24 | ||
| NFD | 74 (59.7) | 27 (77.1)* | 0.014 | 71 (61.7) | 17 (70.8) | 1 |
| NYD | 56 (45.2) | 7 (20.0) | 39 (33.9) | 6 (25.0) | ||
| YFD | 20 (16.1) | 1 (2.9) | 19 (16.5) | 4 (16.7) | ||
| NFY | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.2) | ||
| NYY | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.2) | ||
| YYD | 4 (3.2) | 0 (0.0) | 2 (1.7) | 1 (4.2) | ||
| YFY | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (4.2) | ||
| YYY | 2 (1.6) | 0 (0.0) | 2 (1.7) | 1 (4.2) | ||
Bold letter denotes an encoded amino acid change
†Haplotypes defined at codons 86, 184, and 1246; haplotype numerators include isolates with mixed infections
*Comparing wild-type vs. mutant (excluding mixed infections) for point mutations and NFD versus sum of non-NFD for haplotypes